GHP Q3 2019

GHP / Q3 2019 21 alongside pharma companies who will depend on it to ensure that key decisions are made with the most predictive insights. “For Elsevier, this is another important milestone towards a portfolio which helps the Pharmaceutical industry Elsevier Joins Forces with Pharmaceutical Industry Leaders to Build new Drug-Drug Interaction Risk Calculator in performing better risk- management. With the power of our new versatile data and analytics platform Entellect™, we enable insights across data assets from customers, third-party or any of Elsevier’s content in a very flexible and reusable way.” PharmaPendium’s updated DDIRC will continue to follow FDA Guidelines for mechanistic static prediction of enzyme- mediated DDI risk and could additionally provide information for other models of DDI prediction, such as transporter- mediated DDI risk, based on evaluation partner feedback and feasibility. This increased dataset will allow for more reliable predictions. The new DDIRC is expected to launch in 2020, leveraging the power of our data and analytics platform.